Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells

The use of allogeneic, pluripotent stem‐cell‐derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator‐initiated clinical trials will soon begin for ovarian cancer treatment using human leukocyte antigen (HLA)‐homozygous‐induced pluripotent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Tatsuki, Kumagai, Ayako, Iriguchi, Shoichi, Yasui, Yutaka, Miyasaka, Tadayo, Nakagoshi, Kengo, Nakane, Kazuki, Saito, Keigo, Takahashi, Mari, Sasaki, Aki, Yoshida, Shinsuke, Takasu, Naoko, Seno, Hiroshi, Uemura, Yasushi, Tamada, Koji, Nakatsura, Tetsuya, Kaneko, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226201/
https://www.ncbi.nlm.nih.gov/pubmed/32133731
http://dx.doi.org/10.1111/cas.14374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226201/
https://www.ncbi.nlm.nih.gov/pubmed/32133731
http://dx.doi.org/10.1111/cas.14374

Ejemplares similares